This post is based on an email that was sent and in no way reflects the views and opinions of ''Met'' or Jamaicangroupiemet.com. To send in a story send your email to [email protected]

AVAILABLE FOR ALL THOSE WHO ………..YUH NUH …….

desperate-women

FDA NEWS RELEASE
For Immediate Release: Feb. 26, 2013
Media Inquiries: Stephanie Yao, 301-796-0394, [email protected]
Consumer Inquiries: 888-INFO-FDA

En Español
FDA approves Osphena for postmenopausal women experiencing pain during sex

The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.

Dyspareunia is a condition associated with declining levels of estrogen hormones during menopause. Less estrogen can make vaginal tissues thinner, drier and more fragile, resulting in pain during sexual intercourse.

Osphena, a pill taken with food once daily, acts like estrogen on vaginal tissues to make them thicker and less fragile, resulting in a reduction in the amount of pain women experience with sexual intercourse.

“Dyspareunia is among the problems most frequently reported by postmenopausal women,” said Victoria Kusiak, M.D., deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. “Osphena provides an additional treatment option for women seeking relief.”

Osphena’s safety and effectiveness were established in three clinical studies of 1,889 postmenopausal women with symptoms of vulvar and vaginal atrophy. Women were randomly assigned to receive Osphena or a placebo. After 12 weeks of treatment, results from the first two trials showed a statistically significant improvement of dyspareunia in Osphena-treated women compared with women receiving placebo. Results from the third study support Osphena’s long-term safety in treating dyspareunia.

Osphena is being approved with a boxed warning alerting women and health care professionals that the drug, which acts like estrogen on vaginal tissues, has shown it can stimulate the lining of the uterus (endometrium) and cause it to thicken. In fertile women, this thickening of the endometrium occurs monthly before menstruation. Postmenopausal women no longer experience menstruation, and a stimulated endometrium is not normal. Women should see their health care professional if they experience any unusual bleeding as it may be a sign of endometrial cancer or a condition that can lead to it. Osphena should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.

The boxed warning also states the incidence rates of thrombotic and hemorrhagic strokes (0.72 and 1.45 per thousand women, respectively) and the incidence rate of deep vein thrombosis (1.45 per thousand women). These rates are considered to represent low risks in contrast to the increased risks of stroke and deep vein thrombosis seen with estrogen-alone therapy.

Common side effects reported during clinical trials included hot flush/flashes, vaginal discharge, muscle spasms, genital discharge and excessive sweating.

Osphena is marketed by Florham Park, N.J.-based Shionogi, Inc.

2 Responses to AVAILABLE FOR ALL THOSE WHO ………..YUH NUH …….

  • Foxy Lady says:

    The FDA is the very same agency that approves every other medication that they later withdraw after many fatalities, and severe complications. FDA cannot recommend jack shit to me!

  • PhantomPhoenix says:

    Me see oman come from places whey dem neva know bout menopause and all of a sudden them need chocolate and fan…lololol only in america..

Leave a Reply

Your email address will not be published.

[+] kaskus emoticons nartzco

Current day month [email protected] *

DISCLAIMER The views or opinions appearing on this blog are solely those of their respective authors. In no way do such posts represent the views, opinions or beliefs of “Met,” or jamaicangroupiemet.com. “Met” and jamaicangroupiemet.com will not assume liability for the opinions or statements, nor the accuracy of such statements, posted by users utilizing this blog to express themselves. Users are advised that false statements which are defamatory in nature may be subject to legal action, for which the user posting such statements will be personally liable for any damages or other liability, of any nature, arising out of the posting of such statements. Comments submitted to this blog may be edited to meet our format and space requirements. We also reserve the right to edit vulgar language and/or comments involving topics we may deem inappropriate for this web site.

****RULES**** 1. Debates and rebuttals are allowed but disrespectful curse-outs will prompt immediate BAN 2. Children are never to be discussed in a negative way 3. Personal information  eg. workplace, status, home address are never to be posted in comments. 4. All are welcome but please exercise discretion when posting your comments , do not say anything about someone you wouldnt like to be said about  you. 5. Do not deliberately LIE on someone here or send in any information based on your own personal vendetta. 6. If your picture was taken from a prio site eg. fimiyaad etc and posted on JMG, you cannot request its removal. 7. If you dont like this forum, please do not whine and wear us out, do yourself the favor of closing the screen- Thanks! . To send in a story send your email to :- [email protected]